- Home
- CLS vs BBIO Comparison
CLS vs BBIO Comparison
Compare CLS & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLS
- BBIO
- Stock Information
- Founded
- CLS 1994
- BBIO 2015
- Country
- CLS Canada
- BBIO United States
- Employees
- CLS N/A
- BBIO N/A
- Industry
- CLS Electrical Products
- BBIO Biotechnology: Pharmaceutical Preparations
- Sector
- CLS Technology
- BBIO Health Care
- Exchange
- CLS Nasdaq
- BBIO Nasdaq
- Market Cap
- CLS 9.7B
- BBIO 8.8B
- IPO Year
- CLS 1998
- BBIO 2019
- Fundamental
- Price
- CLS $188.97
- BBIO $49.08
- Analyst Decision
- CLS Strong Buy
- BBIO Strong Buy
- Analyst Count
- CLS 10
- BBIO 16
- Target Price
- CLS $178.20
- BBIO $61.69
- AVG Volume (30 Days)
- CLS 4.0M
- BBIO 2.9M
- Earning Date
- CLS 07-28-2025
- BBIO 08-05-2025
- Dividend Yield
- CLS N/A
- BBIO N/A
- EPS Growth
- CLS 55.91
- BBIO N/A
- EPS
- CLS 4.59
- BBIO N/A
- Revenue
- CLS $10,587,200,000.00
- BBIO $235,812,000.00
- Revenue This Year
- CLS $14.79
- BBIO $106.33
- Revenue Next Year
- CLS $17.67
- BBIO $54.30
- P/E Ratio
- CLS $40.38
- BBIO N/A
- Revenue Growth
- CLS 20.52
- BBIO 7.62
- 52 Week Low
- CLS $40.65
- BBIO $21.72
- 52 Week High
- CLS $218.80
- BBIO $51.86
- Technical
- Relative Strength Index (RSI)
- CLS 52.78
- BBIO 55.76
- Support Level
- CLS $173.23
- BBIO $48.03
- Resistance Level
- CLS $197.49
- BBIO $51.86
- Average True Range (ATR)
- CLS 9.22
- BBIO 1.95
- MACD
- CLS -3.95
- BBIO -0.08
- Stochastic Oscillator
- CLS 34.54
- BBIO 71.55
About CLS Celestica Inc.
Celestica Inc offers supply chain solutions. The company has two operating and reportable segments: Advanced Technology Solutions (ATS) and Connectivity & Cloud Solutions (CCS). The ATS segment consists of the ATS end market and is comprised of the Aerospace and Defense, Industrial, health tech, and Capital Equipment businesses. Its Capital Equipment business is comprised of the semiconductor, display, and robotics equipment businesses, and the CCS segment consists of Communications and Enterprise end markets, The Enterprise end market is comprised of its servers and storage businesses. The company generates a majority of its revenue from the Connectivity & Cloud Solutions segment.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.